Intec Pharma is pleased to report the intermediate results of the first group of patients in the Phase II clinical trials with Accordion Pill Zaleplon.

The analysis of the intermediate results of the trial showed that taking the Zaleplon medication with the Accordion Pill resulted in statistically significant improvement in its effectiveness.

10 patients suffering from chronic Insomnia (sleep disorders) participated in the first group. This double blind study was conducted in sleep clinics in two medical centers in Israel, Rambam and Soroka.The trial examined the effectiveness of the Accordion Pill Zaleplon versus that of a placebo, in a crossover study, by using Polysomnography (comprehensive sleep testing performed at night and includes, among other things, registration of brain waves, eye movements, etc.) The objectives of the trial included, inter alia, evaluating the time to sleep onset, sleep duration and level of alertness the next morning (residual effects of the drug).

An analysis of the intermediate results indicated that in nine out of the ten patients, the following results were achieved:

1.  A statistically significant decrease of the time to sleep onset (LPS- Latency to persistent 
     sleep).

2.  A statistically significant  increase of sleep duration (TST- Total
     sleep time).

3.  No residual effects were found the next morning, following treatment 
     with the Accordion Pill Zaleplon, in comparison to the placebo

According to Dr. Thomas Roth, Director of the Sleep Disorders and Research Center at Henry Ford Health System and Intec's clinical advisor in the field of Insomnia, the Accordion Pill  Zaleplon demonstrated ,in this pilot study,the potential to exhibit better hypnotic effects relative to medications currently on the market.

Pursuant to various publications (Datamonitor, ForecastInsight, Insomnia, Aug 2008), the market for medications for sleep disorders was estimated at approximately US$4.1 billion in the year 2007 in the sevenmajor markets (USA, Japan, UK, France, Germany, Switzerland and Italy) and itis estimated to grow to approximately US$6.8 billion in the seven main marketsby the year 2017.

The Company's estimates regarding future development and expected clinical trials with respect to the Company's products are forward looking information based on information that the Company has in its possession today pertaining to potential drug development and the indications received from relevant health care authorities. These estimates may not be realized, in whole or in part, and/or may be realized differently than estimated as a result of different factors, including the failure to reach the objectives of the trials and/or schedules and/or necessary funding for further drug development as well as failure to obtain regulatory approvals required for further development, failure to reach agreements with international companies, other factors which are not within the Company's control and the materialization of any of the risk factors as detailed in Section 6.31 of the Company`s prospectus filed on February 10, 2010.


Sincerely,

Intec Pharma